A group of biotech CEOs and other drug industry leaders signed a letter published Jan. 8 in STAT promising to price drugs "reasonably" and to improve drug access.
The letter, which the leaders called a "New Commitment to Patients," lists bullet points of "core principles and actions" the leaders promise to follow to ensure access to drugs and to price them responsibly.
"We acknowledge that we have a moral obligation to develop the best medicines and ensure that every person who may benefit has access to them," the leaders wrote.
The leaders promised that the prices of their companies' drugs will "reflect innovation and value to patients" and that "any price increases on our medicines must be reasonable and guided by the need for uninterrupted patient access."
They also promised to collaborate with policymakers, pharmacy benefit managers, payers and providers to work toward eliminating copays and deductibles for all patients.
Read the full letter here.